ABOUT US

Who We Are?

Founded in 1994, Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction and pain management. Rusan’s manufacturing company for active pharmaceutical ingredients (API) and finished pharmaceutical formulations, live up to some of the highest standards of good manufacturing practices (GMP) and are approved by Health Canada.

Rusan Pharma Canada Inc. (RPCI) is the Canadian subsidiary of Rusan Pharma Ltd. (India), a generic pharmaceutical company located in Montreal, Québec. With a strong product development pipeline and strategic partnerships, we pride ourselves in delivering high quality and affordable generic pharmaceutical medicines to the Canadian market. Through product differentiation, best-in-class supply and excellent service, we strive to help families across Canada live longer, healthier and happier lives.

Our Mission

Rusan firmly believes that access to quality healthcare is a right, not a privilege. We will endeavour to ensure the availability of world class, innovative, quality medicines at affordable prices, across the globe and are committed to work towards a healthier & happier world.

Our Vision

To bring forward innovative, highly quality novel and generic medications at affordable prices for our consumers.

Dr. Kunal Saxena

Managing Director, Rusan Pharma

A technocrat with wide exposure to process development, synthetic chemistry & commercialization of bulk drugs. A practicing technocrat with vast experience in research & development. Specialised in computer-aided drug design and new chemical entity synthesis including chiral synthesis. Dr. Kunal Saxena has done his Ph.D. in Pharmacology from the University of Bristol (UK), M.Sc. in Chemistry from Moscow State University (Moscow, Russia) and B.Sc. in Biochemistry from the University of Notre Dame (USA). Has done basic research in the area of opioid receptors and developed several novel non-opioid compounds that help reduce side effects and tolerance to opioid analgesics.

Dr. Aakarsh Saxena

Director, Rusan Pharma

Dr. Aakarsh Saxena, based in Mumbai, is currently a Director at Rusan Pharma Ltd, bringing experience from previous roles at The University of Texas at Austin, The University of Edinburgh, William & Mary and Rusan Pharma Ltd. Dr. Aakarsh Saxena holds a 2008 - 2013 Doctor of Philosophy (Ph.D.) from The University of Edinburgh. With a robust skill set that includes Chemistry, Organic Chemistry, Catalysis, Asymmetric Catalysis, NMR Spectroscopy and more, Dr. Aakarsh Saxena contributes valuable insights to the industry.

Dr. Navin Saxena

Chairman, Rusan Pharma

Ph.D. in Synthetic Organic Chemistry from Moscow Friendship University. Dr. Navin Saxena started his career in 1981 as a Research Officer and within a short span of 10 years reached the level of Vice President and Head of Research. Dr. Navin Saxena is not only the youngest recipient of this award, but also the first Indian to receive this accolade. On 29th July 1997, Dr. Saxena in the capacity of being the Chairman of Rusan Pharma Ltd. was honoured with "THE INTERNATIONAL EXECLLENCE AWARD" by the Council for Small and Medium Exporters for excellence in exporting medicines. Dr. Saxena was also awarded the prestigious "UDYOG RATTAN AWARD" by the Institute for Economic Studies for his contribution in the field of industrial development in India.

API Active Pharmaceutical Ingredient (API)

API Active Pharmaceutical Ingredient (API)

Finished Formulation

All Products

Pain Management

Product Description Strength Fill Size Format Pack Size
RPC - Nalbuphine Injection 10 mg / ml 1 ml Ampoule 10
RPC - Fentanyl Citrate Injection 50 mcg / ml 2 ml Ampoule 10
10 ml 5

Drug Dependence

Product Description Strength Fill Size Format Pack Size
RPC - Methadone Hydrochloride Oral Concentrate (Cherry Flavoured Solution) 10 mg /mI 1000 ml Syrup 1 HDPE Bottle
RPC - Methadone Hydrochloride Oral Concentrate (Dye-Free, Sugar-Free, Unflavored Solution) 10 mg /ml 1000 ml Syrup 1 HDPE Bottle
RPC - Buprenorphine and Naloxone sublingual tablets 8/2 mg - Tablet a. HDPE bottle of 30 tablets
2/0.5 mg b. Alu-Alu blister
RPC - Bisoprolol fumarate tablets 5 mg - Tablet To be decided
2/0.5 mg

Alcohol Dependence

Product Description Strength Fill Size Format Pack Size
RPC - Naltrexone hydrochloride tablets 50 mg NA Tablet a. HDPE bottle of 30 tablets
b. HDPE bottle of 50 tablets
c. PVC-PVDC blister of 10 tablets
ANKLESHWAR (GUJARAT, INDIA)

Approved By

PITHAMPUR (MADHYA PRADESH, INDIA)

Planned

KANDLA UNIT I (GUJARAT, INDIA)
Dosages Form

Tablets

Capsule

Powder in Sachet

Lyo Injectable (Vial / Bulk Powder)

Small Volume Parenteral - Vial

Small Volume Parenteral (Injectable) - Ampoule

Cream & Ointment

Beta-Lactam Capsule

Beta-Lactam Dry Syrup

Approved By

DEHRADUN (UTTARAKHAND, INDIA)
Dosages Form

Tablet

Capsule

Oral Liquid - Solution / Suspension (30 ml to 1000 ml)

Transdermal Patch

Small Volume Parenteral (Injectable) - Vial

Small Volume Parenteral (Injectable) - Ampoule

Small Volume Parenteral (Injectable) - Prefilled Syringe

Approved By

KANDLA UNIT II (GUJARAT, INDIA)
Dosages Form

Transdermal Patch

Oral Film

Approved By

Navin Saxena Research & Technology Pvt. Ltd. (NSRT)

NSRT, an affiliate of Rusan pharma, is a state-of-the-art research centre in the Kandla Special Economic Zone (KASEZ; Gujarat, India). With a rich experience of more than 25 years, in pharmaceutical development & manufacturing, NSRT is capable of undertaking cutting-edge research. Our research team comprises of versatile and specialized pool of scientists in the field of computer aided drug design, development and manufacturing of API and novel drug delivery systems.


NSRT is capable of undertaking R&D projects for custom API synthesis and development of finished formulations and in partnership with Rusan Pharma, undertake commercial production for the Canadian market.

Quantys Clinical Pvt Ltd. (QCPL)

QCPL is a 104 bed clinical research organization (CRO) with five independent clinics with collapsible partitions, enabling QCPL to conduct large, mixed population and multiple studies at the same time. QCPL's  trained & dedicated staff brings in considerable experience in conducting Pharmacokinetic (PK) and Clinical trial studies for various finished formulations.


QCPL's partnerships with Investigators, Institution, NGO’s, Hospitals and Clinics, enable it to recruit not just healthy volunteers but ‘Special Volunteer Groups’ to cater to the specific study requirements.


QCPL can provide PK and clinical trial study services to Canadian Pharmaceutical companies looking to conduct such studies.

Product Pipeline

Innovation is the cornerstone of Rusan’s vision & mission. Our rich development portfolio focuses in the area of addiction treatment, pain management and Parkinson’s. To partner with Rusan on some of our novel & generic transdermal patch products connect with us: formulation.enquiry@rusanpharma.com

Indication Program / Regulatory Pathway Preclinical Phase-I Phase-II Phase-III Approval
Alcohol Use Disorder Antagonist Prodrug Sustained Release Injection (Monthly)
Phase-III
Opioid Use Disorder Partial Agonist Weekly & Monthly Sustained Release Injection
Phase-I
Pain Management Partial Agonist Monthly Sustained Release Injection
Phase-II

Generic Transdermal Patches & Oral Film

For exploring in-licensing opportunities for our transdermal patch portfolio for the Canadian market, please Email us on: formulation.enquiry@rusanpharma.com

Generic Name Remarks
Nicotine Patch Under Development
Nicotine Oral Flim Under Development
Buprenorphine + Naloxone Sublingual Flim Under Development
Buprenorphine Patch Under Development
Fentanyl Patcht Under Development
Rivastigmine Patch Under Development
Rotigitine Patch Under Development
Lidocaine Patch Under Development

CAREERS

"Great Products are the brainchild and hard work of great people. Join a young, dynamic, fast-growing and inclusive company where you have the opportunity to aim high, fulfil your potential, and achieve great things!"

ADR REPORTING

Adr Reporting

Please provide details of the Event(s) that occurred and Product(s) used, as descriptor of the Person who experienced the event and contact details of Reporter.
If you have a medical emergency, please contact your doctor or other health care provider, or emergency services. Please note that Rusan Pharma Canada Inc. is unable to provide medical advice.

47373